Testicular cancer (TC) is the most common neoplasm in males aged 15 to 40 years and approximately 65%-75% have clinical stage I (CSI) disease. Both surveillance and adjuvant chemotherapy may be applied with indistinguishable long-term survival rates. Therefore, the patient should decide based on risk factors and potential benefits and harms rather than adopting a uniform recommendation for al